Initiator Pharma A/S
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor, which completed phase IIb clinical trial primarily targeting the dopamine system for treatment resistant organic erectile dysfunction, as well as completed phase I to t… Read more
Market Cap & Net Worth: Initiator Pharma A/S (INIT)
Initiator Pharma A/S (ST:INIT) has a market capitalization of $18.79 Million (Skr210.83 Million) as of March 18, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #27670 globally and #377 in its home market, demonstrating a 6.21% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Initiator Pharma A/S's stock price Skr3.08 by its total outstanding shares 68452892 (68.45 Million).
Initiator Pharma A/S Market Cap History: 2017 to 2026
Initiator Pharma A/S's market capitalization history from 2017 to 2026. Data shows change from $13.59 Million to $18.79 Million (-4.09% CAGR).
Index Memberships
Initiator Pharma A/S is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$4.63 Billion | 0.26% | #83 of 281 |
Weight: Initiator Pharma A/S's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Initiator Pharma A/S Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Initiator Pharma A/S's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of INIT by Market Capitalization
Companies near Initiator Pharma A/S in the global market cap rankings as of March 18, 2026.
Key companies related to Initiator Pharma A/S by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Initiator Pharma A/S Historical Marketcap From 2017 to 2026
Between 2017 and today, Initiator Pharma A/S's market cap moved from $13.59 Million to $ 18.79 Million, with a yearly change of -4.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr18.79 Million | +4.05% |
| 2025 | Skr18.06 Million | -56.79% |
| 2024 | Skr41.80 Million | -25.87% |
| 2023 | Skr56.38 Million | +52.48% |
| 2022 | Skr36.98 Million | -25.55% |
| 2021 | Skr49.67 Million | +82.29% |
| 2020 | Skr27.25 Million | -39.55% |
| 2019 | Skr45.08 Million | +175.43% |
| 2018 | Skr16.37 Million | +20.42% |
| 2017 | Skr13.59 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Initiator Pharma A/S was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $18.79 Million USD |
| MoneyControl | $18.79 Million USD |
| MarketWatch | $18.79 Million USD |
| marketcap.company | $18.79 Million USD |
| Reuters | $18.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.